BioOhio made the Ohio Statehouse home this morning. President & CEO Tony Dennis joined Dr. Michael Caligiuri, CEO of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, and other officials to talk about the significant economic impact of pharmaceutical clinical trials conducted in Ohio. The We Work for Health press conference focused on a recent PhRMA study, “Research in Your Backyard: Pharmaceutical Clinical Trials in Ohio.”

According to the study, the nation’s biopharmaceutical research companies have conducted nearly 5,000 clinical trials of new medicines in the state since 1999. BioOhio research indicates that more than 30 companies in Ohio are focused on helping pharmaceutical and medical device companies conduct or manage clinical trials.

A couple floors up, BioOhio Sr. Director of Workforce & Education Bill Tacon was delivering testimony in support of HCR 33 in the Senate. HCR is a resolution that urges the U.S. Congress to take action on the federal Workforce Investment Act to allow states greater flexibility to address current economic realities. BioOhio advocates a demand-driven workforce system, where regions and employers convene to identify current workforce needs, resulting in the implementation of training programs in response to forecasted needs.